Recurrent Hyperbilirubinemia with Midostaurin during Consolidation in a Patient of AML with FLT3 Mutation and Review of Literature for Alternative Maintenance Strategy

Abstract

Midostaurin-induced hyperbilirubinemia during consolidation chemotherapy is uncommon. Dose-modification strategy for midostaurin in presence of hyperbilirubinemia remains undefined. We report a case of a young woman diagnosed as acute myeloid leukemia having normal cytogenetics with FLT3-ITD (internal tandem duplication) mutation who tolerated midostaurin during induction but developed recurrent hyperbilirubinemia without transaminitis with midostaurin during high-dose cytarabine consolidation. The pattern of hyperbilirubinemia with midostaurin was transient and rapidly reversible on stopping the drug, but recurred thrice. Sanger sequencing for UGT1A1*28 polymorphism failed to detect relevant variations. In the absence of any other approved FLT3 inhibitor in first line setting, she received sorafenib maintenance at 200 mg twice daily in combination with subcutaneous azacitidine. The combination was well tolerated without hyperbilirubinemia with sorafenib.

Key Message:

Safety of sorafenib in the setting of recurrent hyperbilirubinemia with midostaurin is not known. In this case report the combination of sorafenib with parenteral azacitidine was well tolerated without recurrence of hyperbilirubinemia.

Keywords

AML - FLT3 mutation - midostaurin - hyperbilirubinemia - sorafenib

Authors' Contributions

D.S. was involved in conceptualization, methodology, and writing.

S.K. was involved in supervision and writing.

R.P. helped in data curation and editing.

Patient's Consent

Written informed consent was taken from patient for publishing the case report.

Publikationsverlauf

Artikel online veröffentlicht:
08. Mai 2025

• Reference

• 1 Zhao JC, Agarwal S, Ahmad H, Amin K, Bewersdorf JP, Zeidan AM. A review of FLT3 inhibitors in acute myeloid leukemia. Blood Rev 2022; 52: 100905
• 2 Wang ES, Baron J. Management of toxicities associated with targeted therapies for acute myeloid leukemia: when to push through and when to stop. Hematology (Am Soc Hematol Educ Program) 2020; 2020 (01) 57-66
• 3 Ley TJ, Miller C, Ding L. et al; Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 2013; 368 (22) 2059-2074
• 4 Kiyoi H, Naoe T, Nakano Y. et al. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood 1999; 93 (09) 3074-3080
• 5 Stone RM, Mandrekar SJ, Sanford BL. et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med 2017; 377 (05) 454-464
• 6 Döhner K, Thiede C, Jahn N. et al. Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia. Blood 2020; 135 (05) 371-380
• 7 Uetrecht J, Naisbitt DJ. Idiosyncratic adverse drug reactions: current concepts. Pharmacol Rev 2013; 65 (02) 779-808
• 8 Roboz GJ, Strickland SA, Litzow MR. et al. Updated safety of midostaurin plus chemotherapy in newly diagnosed FLT3 mutation-positive acute myeloid leukemia: the RADIUS-X expanded access program. Leuk Lymphoma 2020; 61 (13) 3146-3153
• 9 Stemler J, Koehler P, Maurer C, Müller C, Cornely OA. Antifungal prophylaxis and novel drugs in acute myeloid leukemia: the midostaurin and posaconazole dilemma. Ann Hematol 2020; 99 (07) 1429-1440
• 10 Ah Y-M, Kim Y-M, Kim M-J. et al. Drug-induced hyperbilirubinemia and the clinical influencing factors. Drug Metab Rev 2008; 40 (04) 511-537
• 11 Cornelissen JJ, Blaise D. Hematopoietic stem cell transplantation for patients with AML in first complete remission. Blood 2016; 127 (01) 62-70
• 12 Oran B, Cortes J, Beitinjaneh A. et al. Allogeneic transplantation in first remission improves outcomes irrespective of FLT3-ITD allelic ratio in FLT3-ITD-positive acute myelogenous leukemia. Biol Blood Marrow Transplant 2016; 22 (07) 1218-1226
• 13 Gaballa S, Saliba R, Oran B. et al. Relapse risk and survival in patients with FLT3 mutated acute myeloid leukemia undergoing stem cell transplantation. Am J Hematol 2017; 92 (04) 331-337
• 14 Reville PK, Kadia TM. Maintenance therapy in AML. Front Oncol 2021; 10: 619085
• 15 Larson RA, Mandrekar SJ, Sanford BL. et al. An analysis of maintenance therapy and post-midostaurin outcomes in the international prospective randomized, placebo-controlled, double-blind trial (CALGB 10603/RATIFY [Alliance]) for newly diagnosed acute myeloid leukemia (AML) patients with FLT3 mutations. Blood 2017; 130 (suppl 1): 145
• 16 Döhner H, Wei AH, Appelbaum FR. et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 2022; 140 (12) 1345-1377
• 17 Erba H, Montesinos P, Vrhovac R. et al. S100: Quizartinib prolonged survival vs placebo plus intensive induction and consolidation therapy followed by single-agent continuation in patients aged 18–75 years with newly diagnosed FLT3–ITD1 AML. HemaSphere 2022; 6: 1-2
• 18 Huls G, Chitu DA, Havelange V. et al; Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON). Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients. Blood 2019; 133 (13) 1457-1464
• 19 Lazenby M, Gilkes AF, Marrin C, Evans A, Hills RK, Burnett AK. The prognostic relevance of flt3 and npm1 mutations on older patients treated intensively or non-intensively: a study of 1312 patients in the UK NCRI AML16 trial. Leukemia 2014; 28 (10) 1953-1959
• 20 Freeman SD, Virgo P, Couzens S. et al. Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia. J Clin Oncol 2013; 31 (32) 4123-4131
• 21 Wei AH, Döhner H, Pocock C. et al; QUAZAR AML-001 Trial Investigators. Oral azacitidine maintenance for acute myeloid leukemia in first remission. N Engl J Med 2020; 383 (26) 2526-2537
• 22 DiNardo CD, Jonas BA, Pullarkat V. et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med 2020; 383 (07) 617-629
• 23 Shukla DK, Katewa S, Porwal R. et al. MRD negative CR after azacitidine and venetoclax in a young patient with AML, unfit for intensive induction followed by ASCT. Leuk Res Rep 2021; 16: 100267
• 24 Bazinet A, Kantarjian H, Borthakur G. et al. A phase II study of azacitidine plus venetoclax as maintenance therapy in acute myeloid leukemia: durable responses with longer term follow-up. Blood 2022; 140 (suppl 1): 9005-9007
• 25 Ivanov V, Yeh SP, Mayer J. et al. Design of the VIALE-M phase III trial of venetoclax and oral azacitidine maintenance therapy in acute myeloid leukemia. Future Oncol 2022; 18 (26) 2879-2889
• 26 Liu T, Ivaturi V, Sabato P. et al; ETCTN-6745 study team. Sorafenib dose recommendation in acute myeloid leukemia based on exposure-FLT3 relationship. [Published correction appears in Clin Transl Sci. 2018 Nov;11(6):624] Clin Transl Sci 2018; 11 (04) 435-443
• 27 Serve H, Krug U, Wagner R. et al. Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial. J Clin Oncol 2013; 31 (25) 3110-3118
• 28 Röllig C, Müller-Tidow C, Hüttmann A. et al. Sorafenib versus placebo in addition to standard therapy in younger patients with newly diagnosed acute myeloid leukemia: results from 267 patients treated in the randomized placebo-controlled SAL-SORAML trial. Blood 2014; 124 (21) 6
• 29 Sasaki K, Kantarjian HM, Kadia T. et al. Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3-internal tandem duplication mutation-positive acute myeloid leukemia. Cancer 2019; 125 (21) 3755-3766
• 30 Pratz KW, Sato T, Murphy KM, Stine A, Rajkhowa T, Levis M. FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML. Blood 2010; 115 (07) 1425-1432